Johnson & Johnson has announced its results for fiscal 2018. The US health care giant saw sales rise 6.7 percent to US$81.6 billion.
Worldwide consumer sales reached US$13.9 billion, an increase of 1.8 percent with Neutrogena, Aveeno and OGX named among the key contributors to growth but pharma was the highlight, growing 12.4 percent to US$40.7 billion.
“Johnson & Johnson delivered another year of strong operational sales growth of 6.4 percent and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8 percent in 2018,” said Alex Gorsky, Chairman and CEO. “This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins. Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investment in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term. Our performance is the result of talented Johnson & Johnson colleagues and their extraordinary dedication to help advance health and well-being for patients and customers around the world.”